AstraZeneca, Sanofi infant respiratory treatment gets US approval

(Sharecast News) – AstraZeneca and Sanofi’s Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.

The treatment is given to those born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus will be available in the US ahead of the upcoming 2023-2024 RSV season, they added.

Related Articles

Sign up to the Wealth DFM Newsletter

Name

Trending Articles

Wealth DFM Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.

Wealth DFM Talk Podcast – listen to the latest episode

Wealth DFM
Privacy Overview

Our website uses cookies to enhance your experience and to help us understand how you interact with our site. Read our full Cookie Policy for more information.